Jump to content

Recommended Posts

Posted

FDA will not require clinical trial data to authorize redesigned COVID boosters -official

NEW YORK (Reuters) - The U.S. Food and Drug Administration will not require companies to submit clinical trial data on COVID-19 vaccines modified to protect against the BA.4 and BA.5 versions of Omicron in order to authorize those shots, a top FDA official said on Thursday.

 

Dr. Peter Marks, head of the agency's Center for Biologics Evaluation and Research, told Reuters the agency will rely on data from clinical trials vaccine makers have run on shots designed to combat the BA.1 lineage, as well as manufacturing data, for emergency use authorization submissions before the fall.

 

https://www.reuters.com/legal/government/fda-will-not-require-clinical-trial-data-authorize-redesigned-covid-boosters-2022-06-30/#:~:text=NEW YORK (Reuters) - The,FDA official said on Thursday. So to expedite this new booster omit possible adverse effects data 

  • Like 1
  • Thanks 1

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.



×
×
  • Create New...